Farkas' Departure a Positive for Sarepta (SRPT) Eteplirsen Approval - Oppenheimer

September 14, 2016 6:28 AM EDT
Get Alerts SRPT Hot Sheet
Price: $34.49 +1.71%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade SRPT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer's Sarepta Therapeutic (NASDAQ: SRPT) analyst Michelle Gilson said their checks suggest that Ronald Farkas, MD, PhD, has indeed left the FDA; additionally, he is no longer listed in the HHS employee directory.

They view this as a positive signal for eteplirsen approval, recalling Dr. Farkas was the team leader who led the review of eteplirsen, and was largely regarded as an antagonistic figure at eteplirsen's advisory committee in May.

Gilson notes the DMD community and experts were particularly inflamed by comments regarding patient effort in the trial and the review's treatment of the data set as if it were not from a rare disease setting.

Contrarily, they would have viewed a promotion for Farkas or departure of a more supportive figure (i.e., Woodcock) as a negative signal for eteplirsen approval.

The firm reiterated an Outperform rating and price target of $60 on SRPT.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $25.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Add Your Comment